Alzheimer's and Dementia: Translational Research and Clinical Interventions
ESCI-ISI SCOPUS (SonsInc.)
2352-8737
Mỹ
Cơ quản chủ quản: WILEY , John Wiley & Sons Inc.
Lĩnh vực:
Psychiatry and Mental HealthNeurology (clinical)
Các bài báo tiêu biểu
Inflammation as a central mechanism in Alzheimer's diseaseAbstract Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized by cognitive decline and the presence of two core pathologies, amyloid β plaques and neurofibrillary tangles. Over the last decade, the presence of a sustained immune response in the brain has emerged as a third core pathology in AD. The sustained activation of the br... ...
Tập 4 Số 1 - Trang 575-590 - 2018
Alzheimer's disease drug development pipeline: 2018Abstract Introduction Treatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug development for AD therapies can be examined by inspecting the drug development pipeline as represented on clinicaltrials.gov . Methods Clinicaltrials.gov was assessed as of January 30, 2018 to determine AD therapies represented in phase I, phase II, and phase III.Results There are 112 agents in the current AD treatment pipeline. There are 26 agents in 35 trials in phase III, 63 agents in 75 trials in phase II, and 23 agents in 25 trials in phase I. A review of the mechanisms of actions of the agents in the pipeline shows that 63% are disease‐modifying therapies, 22% are symptomatic cognitive enhancers, and 12% are symptomatic agents addressing neuropsychiatric and behavioral changes. Trials in phase III are larger and longer than phase II or phase I trials, particularly those involving disease‐modifying agents. Comparison with the 2017 pipeline shows that there are four new agents in phase III, 14 in phase II, and eight in phase I. Inspection of the use of biomarkers as revealed on hiện toàn bộ
Tập 4 Số 1 - Trang 195-214 - 2018
Alzheimer's disease drug development pipeline: 2017Abstract Introduction There is an urgent need to develop new treatments for Alzheimer's disease (AD) and to understand the drug development process for new AD therapies. Methods We assessed the agents in the AD pipeline as documented in hiện toàn bộ
Tập 3 Số 3 - Trang 367-384 - 2017
Sedentary behavior as a risk factor for cognitive decline? A focus on the influence of glycemic control in brain healthAbstract Cognitive decline leading to dementia represents a global health burden. In the absence of targeted pharmacotherapy, lifestyle approaches remain the best option for slowing the onset of dementia. However, older adults spend very little time doing moderate to vigorous exercise and spend a majority of time in sedentary behavior. Sedentary behavior has been li... ...
Tập 3 Số 3 - Trang 291-300 - 2017
Amyloid‐associated increases in longitudinal report of subjective cognitive complaintsAbstract Introduction To investigate whether baseline subjective cognitive complaints (SCCs) predict longitudinal decline on neuropsychological testing and whether SCC increases longitudinally, in the setting of high levels of amyloid burden. Methods Two hundred seventy‐ni...
Tập 4 - Trang 444-449 - 2018
Accelerating drug development for Alzheimer's disease through the use of data standardsAbstract Introduction The exceedingly high rate of failed trials in Alzheimer's disease (AD) calls for immediate attention to improve efficiencies and learning from past, ongoing, and future trials. Accurate, highly rigorous standardized data are at the core of meaningful scientific research. Data standards allow for proper integrat...
Tập 3 - Trang 273-283 - 2017
Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouseAbstract Introduction Translational inhibition of amyloid precursor protein (APP) by Posiphen has been shown to reduce APP and its fragments in cell culture, animal models, and mildly cognitively impaired patients, making it a promising drug candidate for the treatment of Alzheimer's disease. ...
Tập 4 - Trang 37-45 - 2018
Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal imagesAbstract Introduction This study investigates the relationship between retinal image features and β‐amyloid (Aβ) burden in the brain with the aim of developing a noninvasive method to predict the deposition of Aβ in the brain of patients with Alzheimer's disease. Methods R...
Tập 5 - Trang 610-617 - 2019
A model of lipid dysregulation and altered nutrient status in Alzheimer's diseaseAbstract Introduction Dysregulated lipid metabolism and nutrient status are thought to play a role in the pathophysiology of Alzheimer's disease (AD). However, the precise involvement is not well understood, and it remains unclear exactly how such dysregulated lipid metabolism and altered nutrient status, especially changes in phosp...
Tập 5 - Trang 139-145 - 2019
Neural and behavioral substrates of disorientation in mild cognitive impairment and Alzheimer's diseaseAbstract Background The neural and cognitive substrates of measures of orientation as used in clinical trials and examinations have not been comprehensively examined. Methods We studied 473 subjects diagnosed with mild cognitive impairment (MCI) and Alzheimer's disease (AD...
Tập 1 - Trang 37-45 - 2015